{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:47:15Z","timestamp":1773236835423,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Stealth BioTherapeutics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Barth syndrome (BTHS) is a rare, X-linked disorder that stems from mutations in the <jats:italic>TAFAZZIN <\/jats:italic>(TAZ) gene with varying disease severity among patients. The Barth Syndrome Symptom Assessment (BTHS-SA) is a patient-reported outcome questionnaire developed to assess BTHS symptom severity. The current study reflects the first exploration of the assessment\u2019s psychometric performance.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The BTHS-SA was administered in TAZPOWER, a phase 2, randomized, double-blind, placebo-controlled crossover study to evaluate daily subcutaneous injections of elamipretide in subjects with genetically confirmed BTHS. Descriptive and correlational analyses were used to assess the score distributions, reliability, and construct-related validity of BTHS-SA items and domains including a two-item (2 FS), three-item (3 FS), and four-item (4 FS) fatigue score, and a five-item myopathy score (5MS).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among the N\u2009= 12 white males (M age =\u200919.5, SD =\u20097.7) participating in the TAZPOWER trial, overall symptoms were rated as mild (n =\u20095, 41.7%), moderate (n =\u20095, 41.7%), severe (n =\u20091, 8.3%), or very severe (n =\u20091, 8.3%). Descriptive statistics for the BTHS-SA scores indicate variability of symptom severity both within symptom cluster and across patients. Promising results were found for both internal consistency (\u03b1 =\u20090.67, 0.72, and 0.66 for the 3\u2009FS, 4\u2009FS, and 5MS, respectively) and test\u2013retest reliability (ICC values ranging from 0.79 to 0.94 across two test\u2013retest intervals). Correlational analyses showing moderate to strong relationships to other patient reports of fatigue (e.g., r\u2009= 0.59, 0.76, 0.68, and 0.61 between the PROMIS Fatigue SF and the 2\u2009FS, 3\u2009FS, 4\u2009FS, and 5MS, respectively) and symptom severity (e.g., r\u2009= 0.60, 0.62, 0.56, 0.53 between a patient global rating and the 2\u2009FS, 3\u2009FS, 4\u2009FS, and 5MS, respectively) support the measure\u2019s convergent validity. A similar pattern of relationships was observed when correlating changes in BTHS-SA scores to reference measures, including moderate to strong relationships between the BTHS-SA and direct patient reports of change (r =\u20090.81, 0.79, 0.82, and 0.80 between a global impression of change score and the 2\u2009FS, 3\u2009FS, 4\u2009FS, and 5MS, respectively).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Though the small sample size limits strong conclusions, this analysis suggests the BTHS-SA can produce reliable scores upon which valid inferences may be drawn. The BTHS-SA may be a useful tool to evaluate treatment benefits in this underserved population.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>\n              <jats:italic>Trial registration<\/jats:italic>\n            <\/jats:title>\n            <jats:p>ClinicalTrials.gov identifier, NCT03098797. Registered 05 May 2017, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT03098797\" ext-link-type=\"uri\">https:\/\/www.clinicaltrials.gov\/study\/NCT03098797<\/jats:ext-link>.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03693-5","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T18:00:26Z","timestamp":1745604026000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Initial Psychometric Evaluation of the Barth Syndrome Symptom Assessment (BTHS-SA) for Adolescents and Adults in a Phase 2 Clinical Study"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8130-2024","authenticated-orcid":false,"given":"Chad","family":"Gwaltney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Shields","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Love","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Ollis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Stokes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iyar","family":"Mazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ethan","family":"Arenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Aiudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. J.","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie","family":"Houts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"3693_CR1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jpeds.2019.09.074","volume":"217","author":"PC Miller","year":"2020","unstructured":"Miller PC, Ren M, Schlame M, Toth MJ, Phoon CK. A Bayesian analysis to determine the prevalence of Barth syndrome in the pediatric population. J Pediatr. 2020;217:139\u201344.","journal-title":"J Pediatr"},{"issue":"1","key":"3693_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/jimd.12453","volume":"45","author":"R Thompson","year":"2022","unstructured":"Thompson R, Jefferies J, Wang S, Pu WT, Takemoto C, Hornby B, et al. Current and future treatment approaches for Barth syndrome. J Inherit Metab Dis. 2022;45(1):17\u201328.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"3693_CR3","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/ng0496-385","volume":"12","author":"S Bione","year":"1996","unstructured":"Bione S, D\u2019Adamo P, Maestrini E, Gedeon AK, Bolhuis PA, Toniolo D. A novel X-linked gene, G4.5. is responsible for Barth syndrome. Nat Genet. 1996;12(4):385\u20139.","journal-title":"Nat Genet"},{"issue":"4","key":"3693_CR4","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1086\/514886","volume":"61","author":"P D'Adamo","year":"1997","unstructured":"D\u2019Adamo P, Fassone L, Gedeon A, Janssen EA, Bione S, Bolhuis PA, et al. The X-linked gene G4.5 is responsible for different infantile dilated cardiomyopathies. Am J Hum Genet. 1997;61(4):862\u20137.","journal-title":"Am J Hum Genet"},{"key":"3693_CR5","unstructured":"Ferreira C, Thompson R, Vernon H. Barth syndrome. 2014 Oct 9. GeneReviews\u00ae[Internet]. University of Washington, Seattle; 2018."},{"key":"3693_CR6","unstructured":"Medline Plus. Barth syndrome 24\/11\/2021. https:\/\/medlineplus.gov\/genetics\/condition\/barth-syndrome\/"},{"key":"3693_CR7","unstructured":"Barth Syndrome Foundation. What is Barth Syndrome? 2024. https:\/\/www.barthsyndrome.org\/barthsyndrome\/"},{"issue":"2","key":"3693_CR8","doi-asserted-by":"publisher","first-page":"e337","DOI":"10.1542\/peds.2005-2667","volume":"118","author":"CT Spencer","year":"2006","unstructured":"Spencer CT, Bryant RM, Day J, Gonzalez IL, Colan SD, Thompson WR, et al. Cardiac and clinical phenotype in Barth syndrome. Pediatrics. 2006;118(2):e337\u201346.","journal-title":"Pediatrics"},{"issue":"1","key":"3693_CR9","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s13023-019-1200-8","volume":"14","author":"I Mazar","year":"2019","unstructured":"Mazar I, Stokes J, Ollis S, Love E, Espensen A, Barth PG, et al. Understanding the life experience of Barth syndrome from the perspective of adults: a qualitative one-on-one interview study. Orphanet J Rare Dis. 2019;14(1):243.","journal-title":"Orphanet J Rare Dis"},{"key":"3693_CR10","unstructured":"Boston Children's Hospital. Barth Syndrome: Diagnosis and Treatment 2018. http:\/\/www.childrenshospital.org\/conditions-and-treatments\/conditions\/b\/barth-syndrome\/treatments"},{"key":"3693_CR11","unstructured":"Orphanet. Barth Syndrome 4\/3\/2018. http:\/\/www.orpha.net\/consor\/cgi-bin\/OC_Exp.php?lng=EN&Expert=111"},{"key":"3693_CR12","unstructured":"National Institutes of Health. Barth Syndrome 2018. https:\/\/rarediseases.info.nih.gov\/diseases\/5890\/barth-syndrome"},{"issue":"1","key":"3693_CR13","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s13023-021-01897-z","volume":"16","author":"C Gwaltney","year":"2021","unstructured":"Gwaltney C, Stokes J, Aiudi A, Mazar I, Ollis S, Love E, et al. Development and content validity of the Barth Syndrome Symptom Assessment (BTHS-SA) for adolescents and adults. Orphanet J Rare Dis. 2021;16(1):264.","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"3693_CR14","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity\u2014establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1-eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967\u201377.","journal-title":"Value Health"},{"issue":"8","key":"3693_CR15","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity\u2014establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 2-assessing respondent understanding. Value Health. 2011;14(8):978\u201388.","journal-title":"Value Health"},{"key":"3693_CR16","unstructured":"US Department of Health & Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims 2009. https:\/\/www.fda.gov\/media\/77832\/download"},{"issue":"3","key":"3693_CR17","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41436-020-01006-8","volume":"23","author":"WR Thompson","year":"2021","unstructured":"Thompson WR, Hornby B, Manuel R, Bradley E, Laux J, Carr J, et al. A phase 2\/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genet Med. 2021;23(3):471\u20138.","journal-title":"Genet Med"},{"issue":"1","key":"3693_CR18","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1186\/s13023-022-02469-5","volume":"17","author":"B Hornby","year":"2022","unstructured":"Hornby B, Thompson WR, Almuqbil M, Manuel R, Abbruscato A, Carr J, et al. Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome. Orphanet J Rare Dis. 2022;17(1):336.","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"3693_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2024.101138","volume":"26","author":"WR Thompson","year":"2024","unstructured":"Thompson WR, Manuel R, Abbruscato A, Carr J, Campbell J, Hornby B, et al. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genet Med. 2024;26(7): 101138.","journal-title":"Genet Med"},{"issue":"4","key":"3693_CR20","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/NNR.0000000000000162","volume":"65","author":"S Ameringer","year":"2016","unstructured":"Ameringer S, Elswick RK Jr, Menzies V, Robins JL, Starkweather A, Walter J, et al. Psychometric evaluation of the patient-reported outcomes measurement information system fatigue-short form across diverse populations. Nurs Res. 2016;65(4):279\u201389.","journal-title":"Nurs Res"},{"issue":"1","key":"3693_CR21","doi-asserted-by":"publisher","DOI":"10.2196\/10178","volume":"21","author":"G Hernandez","year":"2019","unstructured":"Hernandez G, Garin O, Dima AL, Pont A, Mart\u00ed Pastor M, Alonso J, et al. EuroQol (EQ-5D-5L) validity in assessing the quality of life in adults with asthma: cross-sectional study. J Med Internet Res. 2019;21(1): e10178.","journal-title":"J Med Internet Res"},{"issue":"7","key":"3693_CR22","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28.","journal-title":"Psychiatry (Edgmont)"},{"key":"3693_CR23","unstructured":"Guy W, Bonato RR, US Department of Health E, and Welfare, National Institute of Mental Health. Manual for the ECDEU assessment battery. National Institute of Mental Health, Chevy Chase; 1970."},{"issue":"2","key":"3693_CR24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/jep.12629","volume":"23","author":"RW Bohannon","year":"2017","unstructured":"Bohannon RW, Crouch R. Minimal clinically important difference for change in 6-minute walk test distance of adults with pathology: a systematic review. J Eval Clin Pract. 2017;23(2):377\u201381.","journal-title":"J Eval Clin Pract"},{"issue":"1","key":"3693_CR25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2466\/pms.103.1.215-222","volume":"103","author":"RW Bohannon","year":"2006","unstructured":"Bohannon RW. Reference values for the five-repetition sit-to-stand test: a descriptive meta-analysis of data from elders. Percept Mot Skills. 2006;103(1):215\u201322.","journal-title":"Percept Mot Skills"},{"issue":"2","key":"3693_CR26","first-page":"135","volume":"9","author":"AP Jeremy","year":"2014","unstructured":"Jeremy AP, Amick RZ, Thummar T, Rogers ME. Validation of measures from the smartphone sway balance application: a pilot study. Int J Sports Phys Ther. 2014;9(2):135.","journal-title":"Int J Sports Phys Ther"},{"key":"3693_CR27","volume-title":"Daniels and Worthingham's muscle testing: techniques of manual examination and performance testing","author":"HJ Hislop","year":"2013","unstructured":"Hislop HJ, Avers D, Brown M. Daniels and Worthingham\u2019s muscle testing: techniques of manual examination and performance testing. St. Louis: Slevier Saunders; 2013."},{"issue":"1","key":"3693_CR28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1037\/1082-989X.1.1.30","volume":"1","author":"KO McGraw","year":"1996","unstructured":"McGraw KO, Wong SP. Forming inferences about some intraclass correlation coefficients. Psychol Methods. 1996;1(1):30\u201346.","journal-title":"Psychol Methods"},{"key":"3693_CR29","volume-title":"Applied statistics for the behavioral sciences","author":"DE Hinkle","year":"2003","unstructured":"Hinkle DE, Jurs SG, Wiersma W. Applied statistics for the behavioral sciences. 2nd ed. Boston: Houghton Mifflin; 2003.","edition":"2"},{"issue":"8","key":"3693_CR30","first-page":"783","volume":"48","author":"PL Enright","year":"2003","unstructured":"Enright PL. The six-minute walk test. Respir Care. 2003;48(8):783\u20135.","journal-title":"Respir Care"},{"issue":"12","key":"3693_CR31","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1185\/03007995.2010.532200","volume":"26","author":"DM Bushnell","year":"2010","unstructured":"Bushnell DM, Martin ML, Moore KA, Richter HE, Rubin A, Patrick DL. Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life. Curr Med Res Opin. 2010;26(12):2745\u201355.","journal-title":"Curr Med Res Opin"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03693-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03693-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03693-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T18:00:34Z","timestamp":1745604034000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03693-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3693"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03693-5","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"assertion":[{"value":"5 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The TAZPOWER trial protocol was approved by the Johns Hopkins University School of Medicine Investigational Review Board and the study was performed in accordance with the principles of the Declaration of Helsinki and with the standards of good clinical practice. Written informed consent was obtained from patients and\/or their parent\/guardian. Clinicaltrials.gov registration number NCT03098797.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This manuscript does not contain data from any individual person.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CG has received consulting fees from Stealth BioTherapeutics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"199"}}